Senti Bio reports Q4 net loss $0.6M; two AML patients remain in remission from SENTI-202 trial

Senti Biosciences, Inc.

Q4 net loss $0.6M ($0.67/share); full year net loss $52.8M ($12.03/share).
SENTI-202 Phase 1: 2 of 3 AML patients achieved MRD-negative CR; both still in remission as of March 2025.
Raised $47.6M gross from PIPE in Dec 2024; net $45.1M extends cash runway into 2026.
Cash $48.3M at Dec 31, 2024; received additional $1.5M from CIRM grant in Jan 2025.
Appointed Jay Cross CFO and Faraz Siddiqui SVP Tech Ops in Feb 2025; added two board members.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.